Biogen's diranersen misses Phase II primary endpoint but shows encouraging tau-targeting signal in Alzheimer's

Biogen's diranersen (BIIB080) produced reductions in tau biomarkers and a signal of slowed cognitive decline in early Alzheimer's disease, but the Phase II CELIA study failed its primary endpoint, and a puzzling inversion — where the lowest dose showed the strongest clinical effect — leaves the optimal dosing strategy unresolved ahead of any Phase III program. Data from the randomized, placebo-controlled study [were presented by Biogen](https://app.allsci.com/news/ASC-NR-0000003877390-1.0-1784042470) at the Alzheimer's Association International Conference (AAIC) on July 14, 2026, marking what the Alzheimer's Drug Discovery Foundation (ADDF) described as the first evidence from a randomized trial that a tau-targeting drug can produce both a robust biomarker effect and a signal of clinical benefit. ### What the CELIA data show The [CELIA trial (NCT05399888)](https://clinicaltrials.gov/study/NCT05399888) enrolled patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia and evaluated three intrathecal dosing regimens of diranersen: 60 mg every 24 weeks, 115 mg every 12 weeks, and 115 mg every 24 weeks, over a 76-week placebo-controlled treatment period. The primary endpoint was a dose response-related effect on change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB). The study did not meet that primary endpoint. Across all three doses, CDR-SB results favored diranersen over placebo, but the pattern was not consistent with a dose-response relationship. The lowest dose — 60 mg every 24 weeks — showed a 26% slowing of decline on CDR-SB, a 42% slowing on the ADAS-Cog13 cognitive scale, and a 50% slowing on the MMSE. Exploratory analyses also showed directional slowing of decline on the modified iADRS (30%) and ADCOMS (23%), providing additional support for the observed clinical signal. Biogen reported that tau biomarker reductions were maintained throughout the dosing period across all dose levels studied. Meanwhile, no cases of ARIA were observed, consistent with diranersen's tau-targeting mechanism rather than amyloid removal. ### Dose-response discordance complicates interpretation The central interpretive challenge from CELIA is the divergence between the biomarker and clinical dose-response curves. Higher doses reduced tau more effectively by biomarker measures, yet the lowest dose produced the most pronounced clinical signal. This pattern does not follow the assumptions embedded in the trial's primary endpoint design, and it raises unresolved questions about about whether there is a threshold beyond which additional tau reduction does not translate into greater clinical benefit, or whether the relationship between biomarker change and clinical outcome is nonlinear. Laura Nisenbaum, interim chief science officer at the ADDF, acknowledged the complexity directly: "The dose-response discordance between the biomarker and clinical endpoints raises important questions about the optimal level of tau reduction and the right dose of diranersen to test in subsequent studies." Biogen has said the results support advancing diranersen into further trials and that analysis of the full dataset is ongoing. ### The context [Diranersen](https://app.allsci.com/drugs/ASC-DR-0000000030659-1.0-1772718717) is an antisense oligonucleotide (ASO) administered intrathecally that targets MAPT mRNA, the transcript encoding tau protein. Through an RNase H-mediated cleavage mechanism, it reduces tau production at the transcriptional level, with the goal of slowing tau-driven neurodegeneration. The approach is mechanistically distinct from approved anti-amyloid therapies and is intended to address tau pathology, the second of the two defining hallmarks of Alzheimer's disease. The current approved standard in early Alzheimer's disease is defined by anti-amyloid monoclonal antibodies. Lecanemab (Leqembi), developed by Eisai and Biogen, demonstrated 27% slowing of decline on CDR-SB versus placebo at 18 months in the Phase III [CLARITY AD trial (NCT03887455)](https://clinicaltrials.gov/study/NCT03887455), with an ARIA-E rate of 12.6%. Donanemab (Kisunla), developed by Eli Lilly, reported 35.1% slowing on the integrated Alzheimer's Disease Rating Scale (iADRS) versus placebo at 76 weeks in the low/medium tau population in the Phase III [TRAILBLAZER-ALZ 2 trial (NCT04437511)](https://clinicaltrials.gov/study/NCT04437511), with an ARIA-E rate of 24.0%. Diranersen's lowest-dose clinical signal of 26% slowing on CDR-SB is numerically comparable to lecanemab's Phase III result, though cross-trial comparisons are limited by differences in study design, duration, patient populations, and endpoint weighting. Critically, diranersen targets a different pathological substrate entirely, positioning it as a potential complement to anti-amyloid agents rather than a direct competitor — a rationale that underpins the broader field argument for combination therapy in Alzheimer's disease. The CELIA results do not resolve the question of whether tau reduction translates reliably into clinical benefit, but they provide the field's clearest signal to date that it might. The challenge for Biogen in designing a Phase III program will be selecting the dose that maximizes clinical effect rather than biomarker effect — a distinction CELIA has now made empirically meaningful. Whether that means proceeding with the 60 mg dose, a modified regimen, or a different dosing interval remains under analysis. The ADDF noted that 75% of current Alzheimer's clinical trials are now targeting pathways beyond amyloid and tau, including neuroinflammation, neurotransmitter systems, and metabolic dysfunction. Within that context, the CELIA data provide the strongest randomized clinical evidence to date that lowering tau may translate into clinical benefit, even as the path to a registrational program requires further clarification of the dose-response relationship that this study raised but did not resolve. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/diranersen-alzheimers-cognitive-decline)